National and Kapodistrian University of Athens
Επίπεδα αγγειογενετικών αυξητικών παραγόντων στον ορό ασθενών με μη μικροκυτταρικό καρκίνο πνεύμονα πριν και μετά τη χορήγηση ανοσοθεραπείας, προγνωστική και προβλεπτική αξία
Abstract
dc:descriptionA complex interplay between immune cells and abnormal tumor vasculature in the tumor microenvironment has been previously shown in preclinical studies, while clinical data suggest that angiogenesis biomarkers may be useful as predictors of prognosis and treatment response in immunotherapy-treated solid tumors, including non-small cell lung cancer (NSCLC). Our primary aim was to investigate the prognostic and predictive value of baseline and post-treatment levels of serum vascular endothelial growth factor-A and –B (VEGF-A and VEGF-B, respectively), soluble programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) in patients with advanced NSCLC treated with immune checkpoint inhibitors (ICIs). 55 patients with advanced NSCLC eligible to receive ICIs (as monotherapy or in combination with chemotherapy) were prospectively enrolled. A group of sex- and age-matched healthy controls (n=16) was also recruited, for determination of the optimal cut-offs and the potential diagnostic value of the examined biomarkers. Serum VEGF-A, VEGF-B, sPD-1 and sPD-L1 levels were measured in peripheral blood samples using ELISA, both at baseline and at the time of treatment response evaluation, and were correlated with treatment response, prognosis (PFS, OS), and the remaining clinicopathological features of patients. The mean age of patients was 66.5 years (SD=8.0 years); 65.5% of patients received chemotherapy and pembrolizumab combination while the remaining patients received pembrolizumab monotherapy. VEGF-B and sPD-1 levels were significantly decreased and increased, respectively, after treatment (p=0.028 and p<0.001, respectively). VEGF-A and sPD-L1 levels also decreased and increased, respectively, albeit without reaching statistical significance. ROC analysis showed that only VEGF-B and sPD-1 had significant value in discriminating between patients and controls. Univariate Cox regression analysis showed that increased pre-treatment values of sPD-1 (HR=10.96; p=0.037) and sPD-L1 (HR=1.68; p=0.040) and increased post-treatment levels of VEGF-B (HR=2.99; p=0.049) were all significantly associated with reduced OS. VEGF-B and sPD-L1 retained their prognostic significance in multivariate analysis (HR=3.37; p=0.032 and HR=2.10; p=0.014, respectively). The results of the study revealed that sPD-L1 and VEGF-B may represent independent biomarkers of prognosis in advanced-stage NSCLC patients treated with ICIs.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kokkotou, Eleni
- Κόκκοτου, Ελένη
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60242